Cargando…
Nasogastric tube‐administered alectinib achieved long‐term survival in a crizotinib‐refractory nonsmall cell lung cancer patient with a poor performance status
Alectinib shows remarkable efficacy against anaplastic lymphoma kinase (ALK)‐positive nonsmall cell lung cancer (NSCLC), with minimal adverse effects. Therefore, alectinib may provide a survival benefit to ALK‐positive NSCLC patients with a poor performance status. If the medication cannot be taken...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5458002/ https://www.ncbi.nlm.nih.gov/pubmed/28588841 http://dx.doi.org/10.1002/ccr3.973 |